Vertex Pharmaceuticals: Strong Financial Performance and Promising Future Prospects Justify Buy Rating
Phil Nadeau, an analyst from TD Cowen, maintained the Buy rating on Vertex Pharmaceuticals (VRTX – Research Report). The associated price ...
Vertex Pharmaceuticals Tops Q3 Estimates
Vertex also reported a steady increase in its R&D and SG&A expenses, reflecting its aggressive investment in pipeline ...
Investor's Business Daily on MSN9h
Vertex Beats Expectations, But Needs More To Drive 'Another Leg Of Stock Upside'
Vertex beat third-quarter expectations late Monday, but an analyst says Vertex stock needs more "to drive another leg of stock upside." ...
Zacks.com on MSN9h
Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Top Estimates
Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.38 per share, beating the Zacks Consensus Estimate of $4.13 per share. This compares to earnings of $4.08 per share a year ago.
Vertex Pharmaceuticals Raises Full-Year Outlook After 3Q Earnings
Vertex Pharmaceuticals again raised its full-year outlook after posting earnings and revenue growth in the third quarter. The biotechnology company on Monday posted a quarterly net profit of $1.05 ...